方法对比
并排查看您选择的方法；存在差异的行会高亮显示。
| 成本-效益分析 (CEA)× | 生命质量调整年 (QALY)× | |
|---|---|---|
| 领域 | 卫生经济学 | 卫生经济学 |
| 方法族 | Process / pipeline | Process / pipeline |
| 起源年份≠ | 1984 | 1985 |
| 提出者≠ | Drummond & Stoddart (Health Economics Research Group, McMaster University) | Alan Williams (Health Economics Research Centre, Oxford University) |
| 类型 | Method | Method |
| 开创性文献≠ | Gold, M. R., Siegel, J. E., Russell, L. B., & Weinstein, M. C. (Eds.). (1996). Cost-Effectiveness in Health and Medicine. New York: Oxford University Press. link ↗ | Kind, P. (1989). The EuroQol instrument: an index of health-related quality of life. In B. Teeling Smith (Ed.), Measuring health: a practical approach. Chichester: Wiley. link ↗ |
| 别名≠ | CEA, ICER, Incremental Cost-Effectiveness Ratio | QALY, health utility measure |
| 相关 | 5 | 5 |
| 摘要≠ | Cost-effectiveness analysis compares the incremental cost per unit of health benefit gained by one intervention relative to a comparator (standard care or best alternative). Developed rigorously in the 1980s by Drummond, Stoddart, and colleagues, CEA is now the standard framework for technology appraisal globally. NICE, HAS, CADTH, and other health technology assessment bodies use CEA to decide which treatments warrant public funding and at what price. | A QALY measures health benefit as utility weight (0 = death, 1 = perfect health) multiplied by time lived. Developed by Alan Williams in 1985, QALYs enable comparison of disparate health interventions on a common metric. Used globally by health technology assessment bodies—NICE (UK), HAS (France), CADTH (Canada), WHO—to decide which treatments deserve public funding. |
| ScholarGate数据集 ↗ |
|
|